ISIS 2922 antisense compound: Began Phase III trial

One will compare time to disease progression with ISIS 2922 plus ganciclovir with ganciclovir alone. The ganciclovir combination study will involve patients whose CMV retinitis has progressed at least once while they were being treated with gancyclovir or foscarnet.

The second protocol will compare immediate treatment with the antisense agent to delayed therapy, i.e. no therapy until disease progression. This trial will involve patients newly diagnosed with the disease. ...